Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 3/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | TYK2 | P29597 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521409 | 0.90 | BTK (0.39) | PIN1MAP3K12JAK3BTKSLC6A7 | |
| SCHEMBL4520280 | 0.85 | MAP3K12 (0.38) | PIN1MAP3K12JAK3BTK | |
| SCHEMBL4524529 | 0.82 | JAK3 (0.34) | PIN1JAK3CCR4JAK1TYK2 | |
| SCHEMBL4512965 | 0.80 | AXL (0.35) | CCR4IGF1RAPPHCRTR1HCRTR2 | |
| SCHEMBL4512389 | 0.79 | AXL (0.36) | CCR4IGF1RAPPHCRTR1HCRTR2 | |
| SCHEMBL4521438 | 0.79 | IGF1R (0.40) | MAP3K12JAK3IGF1RJAK1TYK2 | |
| SCHEMBL4512984 | 0.78 | HSD17B10 (0.49) | — | |
| SCHEMBL4535405 | 0.76 | AURKA (0.37) | PIN1JAK3BTKPARP1 | |
| SCHEMBL4521519 | 0.76 | CCR4 (0.36) | CCR4IGF1RAPPHCRTR1HCRTR2 | |
| SCHEMBL4515702 | 0.76 | PRKCQ (0.34) | JAK3CCR4TYK2JAK2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | PIN1 1927/4885MAP3K12 3670/4885JAK3 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.